TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37634144

Group type: EXPERIMENTAL
Intervention: iFR-guided revascularization
Number of subjects: 4511

Group type: COMPARATOR
Intervention: FFR-guided revascularization
Number of subjects: 4511
Study: 37634145

Group type: EXPERIMENTAL
Intervention: ECLS plus usual medical treatment
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (usual medical treatment alone)
Number of subjects: 420
Study: 37634148

Group type: EXPERIMENTAL
Intervention: Pulsed field ablation
Number of subjects: 607

Group type: COMPARATOR
Intervention: Conventional thermal ablation
Number of subjects: 607
Study: 37634149

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1201
Study: 37634150

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Culprit-only revascularization
Number of subjects: 1445
Study: 37634187

Group type: EXPERIMENTAL
Intervention: CMR-guided TAVR
Number of subjects: 380

Group type: COMPARATOR
Intervention: CT-guided TAVR
Number of subjects: 380
Study: 37634188

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 2487

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 2487
Study: 37634190

Group type: EXPERIMENTAL
Intervention: Immediate multivessel PCI
Number of subjects: 840

Group type: COMPARATOR
Intervention: Staged multivessel PCI
Number of subjects: 840
Study: 37634234

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (DXM20)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Standard of care 6 mg dose of dexamethasone (DXMSoC)
Number of subjects: 473
Study: 37634517

Group type: EXPERIMENTAL
Intervention: Immediate isoniazid preventive therapy (28 weeks isoniazid [300 mg daily], then placebo until week 40 after delivery)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Deferred treatment (placebo until week 12 after delivery, then isoniazid [300 mg daily] for 28 weeks)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Immediate isoniazid preventive therapy
Number of subjects: 749

Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 749
Study: 37634520

Group type: EXPERIMENTAL
Intervention: Adaptive CRT (synchronised left ventricular stimulation)
Number of subjects: 3617

Group type: COMPARATOR
Intervention: Conventional CRT (biventricular CRT)
Number of subjects: 3617
Study: 37634629

Group type: EXPERIMENTAL
Intervention: anti-PD-1 inhibitor in combination with standard systemic treatment
Number of subjects: 15
Study: 37634655

Group type: EXPERIMENTAL
Intervention: Anti-factor Xa NOAC (apixaban 5 mg twice per day, edoxaban 60 mg daily, or rivaroxaban 20 mg daily for 12 months)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Safety Composite of VARC-3 bleeding events, thromboembolic events (myocardial infarction and stroke), and death from any cause at 12 months
Number of subjects: 360

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 75 mg daily indefinitely (control group)
Number of subjects: 360
Study: 37634707

Group type: EXPERIMENTAL
Intervention: Continuing SGLT2 inhibitors in patients with HF and eGFR <25 mL/min/1.73 m²
Number of subjects: 11007
Study: 37634859

Group type: EXPERIMENTAL
Intervention: ABP-ADC < 33%
Number of subjects: 273

Group type: COMPARATOR
Intervention: ABP-ADC group (30-35%)
Number of subjects: 273

Group type: COMPARATOR
Intervention: ABP-ADC group (>35%)
Number of subjects: 273

Group type: COMPARATOR
Intervention: ABP-ADC group (<30%)
Number of subjects: 273
Study: 37635157

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study: 37635160

Group type: EXPERIMENTAL
Intervention: Dynamic warm-up intervention (DWU)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Hybrid warm-up intervention (HWU)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Stretching warm-up intervention (SWU)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No warm-up intervention (CONTROL)
Number of subjects: 92
Study: 37635200

Group type: EXPERIMENTAL
Intervention: Endoscopic Group (EG) - endoscopic untwist of sigmoid colon followed by endoscopic fixation under sedation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Surgical Group (SG) - surgical fixation of sigmoid colon or sigmoidectomy after initial simple loop colostomy under general anesthesia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 37635707

Group type: EXPERIMENTAL
Intervention: BASET score
Number of subjects: 144

Group type: COMPARATOR
Intervention: STOP-Bang score
Number of subjects: 144

Group type: COMPARATOR
Intervention: Berlin score
Number of subjects: 144
Study: 37635769

Group type: EXPERIMENTAL
Intervention: Night-time only subcutaneous apomorphine infusion
Number of subjects: 42
Study: 37635784

Group type: EXPERIMENTAL
Intervention: Aortic flow parameters derived from 2D phase-contrast cardiovascular magnetic resonance imaging
Number of subjects: 169
Study: 37635813

Group type: EXPERIMENTAL
Intervention: NCCN resectability status classification
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Assessment of vascular invasion
Number of subjects: 69
Study: 37635815

Group type: EXPERIMENTAL
Intervention: Induction systemic therapy with doublet or triplet chemotherapy plus targeted therapy
Number of subjects: 173
Study: 37635843

Group type: EXPERIMENTAL
Intervention: Home-based computerized training with Web-based cognitive games
Number of subjects: 107

Group type: COMPARATOR
Intervention: Web-based crossword puzzles
Number of subjects: 107
Study: 37635913

Group type: EXPERIMENTAL
Intervention: One motivational interviewing session plus up to four weeks of patient navigation
Number of subjects: 440

Group type: COMPARATOR
Intervention: One motivational interviewing session
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 440
Study: 37636251

Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5%
Number of subjects: 535
Study: 37636253

Group type: EXPERIMENTAL
Intervention: E-BPO cream, 5%
Number of subjects: 733

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 733
Study: 37636296

Group type: EXPERIMENTAL
Intervention: Pre- and/or postconditioning treatment in addition to conventional percutaneous coronary intervention
Number of subjects: 566

Group type: COMPARATOR
Intervention: Conventional percutaneous coronary intervention
Number of subjects: 566
Study: 37637060

Group type: EXPERIMENTAL
Intervention: Supradiaphragmatic lymphadenectomy during primary debulking surgery (PDS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Interval debulking surgery after neoadjuvant chemotherapy (IDS/NAC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Residual tumors in the abdominal area measuring ≥5 mm
Number of subjects: 120
Study: 37637187

Group type: EXPERIMENTAL
Intervention: TEA + PPI
Number of subjects: 66

Group type: COMPARATOR
Intervention: PPI
Number of subjects: 66
Study: 37637218

Group type: EXPERIMENTAL
Intervention: Ticagrelor plus aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 37637234

Group type: EXPERIMENTAL
Intervention: Presence of autoimmune allele
Number of subjects: 55
Study: 37637440

Group type: EXPERIMENTAL
Intervention: High ligation (HL)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Low ligation (LL)
Number of subjects: 196
Study: 37637501

Group type: EXPERIMENTAL
Intervention: TAE-iNKT (Transarterial Embolization with biweekly iNKT cell infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAE (Transarterial Embolization without iNKT cell infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TAE-iNKT
Number of subjects: 60
Study: 37637850

Group type: EXPERIMENTAL
Intervention: Transcutaneous afferent patterned stimulation (TAPS) therapy, unsupervised at-home sessions twice daily for four weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transcutaneous afferent patterned stimulation (TAPS) therapy
Number of subjects: 40
Study: 37637880

Group type: EXPERIMENTAL
Intervention: Total Tumor Volume (TTV) response assessment
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: TTV decrease of more than 10%
Number of subjects: 210

Group type: COMPARATOR
Intervention: RECIST1.1
Number of subjects: 210
Study: 37637902

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 36
Study: 37637935

Group type: EXPERIMENTAL
Intervention: M8891 (7-80 mg once daily in 21-day cycles)
Number of subjects: 27
Study: 37638077

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane 3 ml
Number of subjects: 15

Group type: COMPARATOR
Intervention: i.v. fentanyl 25 μg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 37638079

Group type: EXPERIMENTAL
Intervention: ObsQoR-10-French questionnaire at H24 after delivery
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ObsQoR-10-French questionnaire at H48 after delivery
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ObsQoR-10-French questionnaire before delivery
Number of subjects: 500
Study: 37638083

Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (control group)
Number of subjects: 0
Study: 37638086

Group type: EXPERIMENTAL
Intervention: TI.VA algorithm for anaesthesia management
Number of subjects: 9

Group type: COMPARATOR
Intervention: Manual control using propofol and remifentanil
Number of subjects: 9
Study: 37638196

Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (EVT)
Number of subjects: 3000
Study: 37638400

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once-daily
Number of subjects: 744
Study: 37638409

Group type: EXPERIMENTAL
Intervention: Nonthermal Point-by-Point Pulmonary Vein Isolation using a Novel Pulsed Field Ablation System
Number of subjects: 0
Study: 37638435

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT) 24 cGy/6 fractions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT) 300 cGy/6 fractions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham radiation therapy (0 cGy/6 fractions)
Number of subjects: 60
Study: 37638695

Group type: EXPERIMENTAL
Intervention: Muvalaplin (30 mg to 800 mg daily for 14 days)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Muvalaplin (single ascending dose of 1 mg to 800 mg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Muvalaplin (multiple ascending dose)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Muvalaplin
Number of subjects: 114
Study: 37638789

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study: 37638838

Group type: EXPERIMENTAL
Intervention: Pecan-enriched diet (68 g of pecans/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study: 37638882

Group type: EXPERIMENTAL
Intervention: Knowledge of treatment options
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Awareness of treatment options offered
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Management of PAD
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Treatment goal rankings
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Variability in treatment goal importance
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Most important treatment goal
Number of subjects: 281
Study: 37638968

Group type: EXPERIMENTAL
Intervention: 12-month edoxaban treatment
Number of subjects: 601

Group type: COMPARATOR
Intervention: 3-month edoxaban treatment
Number of subjects: 601
Study: 37639169

Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg intravenously every 3 weeks for 12 months
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patisiran 0.3 mg/kg q3w
Number of subjects: 23
Study: 37639243

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo crossover to Mavacamten
Number of subjects: 108
Study: 37639259

Group type: EXPERIMENTAL
Intervention: Mavacamten (2.5 mg once daily for 30 weeks)
Number of subjects: 81
Study: 37639272

Group type: EXPERIMENTAL
Intervention: MR-supported care (MR-SC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 22
Study: 37639295

Group type: EXPERIMENTAL
Intervention: MeT4VeT app (full app)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Noninteractive app with signposting information (control)
Number of subjects: 50
Study: 37639296

Group type: EXPERIMENTAL
Intervention: Smartphone-based bodily interventions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Smartphone-based fairy tale interventions (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both intervention types
Number of subjects: 36
Study: 37639299

Group type: EXPERIMENTAL
Intervention: Virtual Worlds (VW) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asynchronous web-based PTSD training
Number of subjects: 0
Study: 37639601

Group type: EXPERIMENTAL
Intervention: Nicotinic acetylcholine receptor agonist
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 37639651

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 156
Study: 37639723

Group type: EXPERIMENTAL
Intervention: Colonoscopy with computer-aided detection
Number of subjects: 3213

Group type: COMPARATOR
Intervention: Colonoscopy without computer-aided detection (Control)
Number of subjects: 3213
Study: 37639751

Group type: EXPERIMENTAL
Intervention: Preoxygenation with forced ventilation at 8 breaths/min for 1 minute
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: dPVi (difference in pleth variability index)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: %PVi (percentage of change in pleth variability index)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: %PVi
Number of subjects: 87
Study: 37639777

Group type: EXPERIMENTAL
Intervention: Gaboxadol (0.125 mg/kg to 0.24 mg/kg based on weight)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Gaboxadol
Number of subjects: 104
Study: 37639820

Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Chemotherapy or oral targeted therapy
Number of subjects: 1973

Group type: EXPERIMENTAL
Intervention: Oral targeted therapy
Number of subjects: 1973

Group type: COMPARATOR
Intervention: Active cancer treatment
Number of subjects: 1973
Study: 37640025

Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody plus anti-vascular endothelial growth factor receptor 2 inhibitors and eribulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lipid proteomics model consisting of six metabolites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: treatment
Number of subjects: 0
Study: 37640035

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily
Number of subjects: 3209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3209
Study: 37640232

Group type: EXPERIMENTAL
Intervention: Bayley-III cognitive scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayley-III language scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayley-III cognitive composite score cut point of 92
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayley-III language composite score cut point of 88
Number of subjects: 0
Study: 37640248

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 37640458

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Single anastomosis sleeve ileal (SASI) bypass
Number of subjects: 113
Study: 37640452

Group type: EXPERIMENTAL
Intervention: ECAP-controlled closed-loop SCS (CL-SCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-output open-loop SCS (OL-SCS)
Number of subjects: 0
Study: 37640455

Group type: COMPARATOR
Intervention: Fluconazole (control)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Medical grade honey (L-Mesitran, treatment)
Number of subjects: 252
Study: 37640469

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post-tetanic count of 1-2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four count of 1-2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 100
Study: 37640625

Group type: EXPERIMENTAL
Intervention: Anakinra 100mg daily subcutaneous dose during hospitalization
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 37640679

Group type: EXPERIMENTAL
Intervention: CAR-NK cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR-Macrophages (CAR-Ms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR-T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR-Macrophages (CAR-M)
Number of subjects: 0
Study: 37640781

Group type: EXPERIMENTAL
Intervention: Pediatric QoR-15F score on postoperative day 1 (POD1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patient-rated global recovery assessment
Number of subjects: 150
Study: 37640809

Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline supplementation (100 mg/kg/day) for 7 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline supplementation (200 mg/kg/day) for 7 days
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enteral L-citrulline supplementation (300 mg/kg/day) for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study: 37640861

Group type: EXPERIMENTAL
Intervention: Natriuresis-guided therapy
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 310
Study: 37640860

Group type: EXPERIMENTAL
Intervention: Bivalent variant vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monovalent variant vaccines
Number of subjects: 0
Study: 37640889

Group type: EXPERIMENTAL
Intervention: Dynamic model using baseline demographic data and serially collected blood samples and transvaginal sonographies
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Fetal heart rate detected before 8 weeks' gestation
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Maternal age (≥ 35 years), insufficient crown-rump-length (CRL), mean gestational sac diameter (MSD) development, presence of bleeding
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Serum biomarkers including hCG, progesterone, and estradiol
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Combination of maternal age, vaginal bleeding, CRL, and hCG
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Sonography-absent model of maternal age, bleeding, hCG, and estradiol
Number of subjects: 203
Study: 37640898

Group type: EXPERIMENTAL
Intervention: Circumferential peak early diastolic strain rate (PEDSR)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Reduction of PEDSR by 0.1/s
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: PEDSR ≤ 0.485/s
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: PEDSR added to conventional prognostic factors
Number of subjects: 420
Study: 37641013

Group type: EXPERIMENTAL
Intervention: CEN (Central Executive Network)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SN (Salience Network)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DMN (Default Mode Network)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Resting-state functional connectivity of the IPL and DLPFC in the CEN
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CEN (at six-month follow-up)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SN and DMN (at six-month follow-up)
Number of subjects: 17
Study: 37641020

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control
Number of subjects: 123
Study: 37641082

Group type: EXPERIMENTAL
Intervention: Cerclage fixation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tension band wiring
Number of subjects: 200
Study: 37641122

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 31

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 31
Study: 37641136

Group type: EXPERIMENTAL
Intervention: FX06 (400 mg/d, for 5 days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: FX06
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 37641544

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study: 37641555

Group type: EXPERIMENTAL
Intervention: Aneurysm treatment <6 h after rupture
Number of subjects: 497

Group type: COMPARATOR
Intervention: Aneurysm treatment 6-24 h after rupture
Number of subjects: 497
Study: 37641579

Group type: EXPERIMENTAL
Intervention: Upper-extremity muscle strength
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Lower-extremity strength
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: SVC (Slow Vital Capacity)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Upper- and lower-extremity strength
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Muscle strength quantified by dynamometry
Number of subjects: 456
Study: 37641586

Group type: EXPERIMENTAL
Intervention: Active Intradermal Acupuncture combined with SSRIs (AIA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham Intradermal Acupuncture combined with SSRIs (SIA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)-only group
Number of subjects: 120
Study: 37641718

Group type: EXPERIMENTAL
Intervention: Postdischarge video visit (2-5 days postdischarge) in addition to usual care
Number of subjects: 1190
Study: 37641932

Group type: EXPERIMENTAL
Intervention: Isavuconazole
Number of subjects: 0
Study: 37641966

Group type: EXPERIMENTAL
Intervention: Patients with advanced DCM (LVAD/HT)
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Patients with ICD only
Number of subjects: 1198

Group type: COMPARATOR
Intervention: Patients with neither LVAD/HT nor ICD
Number of subjects: 1198
Study: 37642032

Group type: EXPERIMENTAL
Intervention: Post-PCI fractional flow reserve measurement after drug-eluting stent implantation; identified adverse clinical characteristics include age ≥65 years, diabetes, chronic kidney disease, left ventricular ejection fraction <50%; identified adverse vessel characteristics include post-PCI fractional flow reserve ≤0.80 and total stent length ≥54 mm.
Number of subjects: 2081